Safety and Efficacy of Thrombin-JMI: A Multidisciplinary Expert Group Consensus

Bhandari, Mohit; Ofosu, Frederick A.; Mackman, Nigel; Jackson, Craig M.; Doria, Cataldo; Humphries, John Eric; Babu, Sateesh; Ortel, Thomas L.; Thiel, David H. Van; Walenga, Jeanine M.; Wahi, Rakesh; Teoh, Kevin; Fareed, Jawed

doi:10.1177/1076029610385674

Cited by 7 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One year later, the FDA approved another thrombin‐based product—recombinant human thrombin, providing another potential alternative that has an equal capability to bovine thrombin and can get rid of the antigenicity risk. [ 38,40 ]…”

Section: Clinical Evaluation Of Thrombin: Bovine Thrombin Human Throm...mentioning

confidence: 99%

“…One year later, the FDA approved another thrombin-based product-recombinant human thrombin, providing another potential alternative that has an equal capability to bovine thrombin and can get rid of the antigenicity risk. [38,40] Bovine thrombin, human thrombin, and recombinant human thrombin have been utilized for hemostasis control when blood oozing from venules and capillaries is approachable, as well as when typical surgical procedures are not able to control the bleeding. [37,[41][42][43] Thrombin can be combined with various hemostatic agents like absorbable materials (including oxidized regenerated cellulose, gelfoam, and microfibrillar collagen), or further mixed with fibrinogen in the formation of fibrin glues.…”

Section: Clinical Evaluation Of Thrombin: Bovine Thrombin Human Throm...mentioning

confidence: 99%

See 1 more Smart Citation

Thrombin and Thrombin‐Incorporated Biomaterials for Disease Treatments

Zhang,

Duan,

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Thrombin, a coagulation‐inducing protease, has long been used in the hemostatic field. During the past decades, many other therapeutic uses of thrombin have been developed. For instance, burn treatment, pseudoaneurysm therapy, wound management, and tumor vascular infarction (or tumor vasculature blockade therapy) have all utilized the unique and powerful function of thrombin. Based on their therapeutic effects, many thrombin‐associated products have been certificated by the Food and Drug Administration, including bovine thrombin, human thrombin, recombinant thrombin, fibrin glue, etc. Besides, several thrombin‐based drugs are currently undergoing clinical trials. In this article, we summarize the therapeutic uses of thrombin (from the initial hemostasis to the latest cancer therapy), the commercially available drugs associated with thrombin, and the pros and cons of thrombin‐based therapeutics (e.g., adverse immune responses related to bovine thrombin, thromboinflammation, and vasculogenic “rebounds”). Further, we discuss the current challenges and possible future research directions of thrombin‐incorporated biomaterials and therapies. It is hoped that this review may provide a valuable reference for researchers in this field and help them to design safer and more effective thrombin‐based drugs for fighting against various intractable diseases.This article is protected by copyright. All rights reserved

show abstract

Section: Clinical Evaluation Of Thrombin: Bovine Thrombin Human Throm...mentioning

confidence: 99%